Deals in Depth: January 2008
Executive Summary
January 2008 dealmaking highlights: Genzyme gets rights to Isis' Phase II cholesterol-reducing agent mipomersen in alliance valued at $1.2bn; M&A dollar volume saw a steep decline compared with the several-billion-dollar+ deals signed in the previous couple months across all industries; and device financing from IPOs and FOPOs decreased 96% from December to $13mm in January, the lowest amount of public financing within the last six months.